Recently it has been shown that using an allosteric AKT1/2/3 inhibitor in CRC patients does not result in the desired reduction in PKB phosphorylation levels, and therefore does not have clinical value [45]. This evidence concerns the gene AKT1 and colorectal carcinoma.